Cardiff Oncology presented new preclinical data showing that onvansertib, an oral PLK1 inhibitor, combined with trastuzumab deruxtecan (T-DXd), a HER2-targeted antibody-drug conjugate, significantly improved tumor regression and apoptosis in HER2-low breast cancer models, including resistant types. This combination demonstrated enhanced tumor growth inhibition, increased survival, and good tolerability in animal studies, highlighting a promising treatment option for patients with limited therapies. The data were shared at the 2026 AACR Annual Meeting, supporting further clinical development of onvansertib in combination with ADCs for difficult-to-treat cancers.
The Rosen Law Firm is investigating potential securities claims against Putnam Investment Management, LLC, alleging that the company may have provided misleading business information to investors. Investors who purchased Putnam stock-based mutual fun...
Several stocks experienced significant declines today driven by company-specific events. SANUWAVE Health's shares dropped 39.21% despite strong revenue guidance, Twin Vee Powercats fell 30.95% amid a legal investigation, and Gorilla Technology declin...
The phase III ENDURANCE trial showed that two years of lenalidomide maintenance therapy offers the same long-term survival benefit as indefinite treatment for patients with standard-risk multiple myeloma who are not transplant candidates. After nearl...
The stock market saw significant gains driven by corporate announcements and high trading volumes, particularly in battery technology, electric vehicles, and green energy sectors. Electrovaya surged 49.05% after announcing a commercial deal with Amaz...
An Akamai Technologies executive sold 3,100 shares as the company shifts focus from its declining content delivery network business to high-growth cloud infrastructure and cybersecurity services. This strategic pivot is supported by a $1.8 billion, s...
